HX 044
Alternative Names: HX-044Latest Information Update: 09 Dec 2024
Price :
$50 *
At a glance
- Originator HanX Biopharmaceuticals
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 30 Nov 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease) in Australia (unspecified route) (NCT06649708)
- 21 Oct 2024 Hanx Biopharmaceuticals plans a phase I/II trial for Solid tumours (Late-stage disease) in Australia (NCT06649708, HX044-I-01)
- 21 Oct 2024 Preclinical trials in Solid tumours in China (unspecified route), prior to October 2024 (Hanx Biopharmaceuticals pipeline, October 2024)